



Attn: Trading and Market Making/Legal and Compliance/Operations/Systems
UNIFORM PRACTICE ADVISORY (UPC #69-24) 10/02/2024 Phasebio
Pharmaceuticals, Inc (PHASQ)

Notice has been received that the above Company's Amended Combined Disclosure Statement And Chapter 11 Plan became effective on 09/30/2024. Pursuant to the plan, On the Effective Date, (i) In the event that Holders of Class 3 General Unsecured Claims are not paid in full, Holders of Class 4 Equity Interests shall not receive or retain any distribution under the Combined Disclosure statement and Plan on account of such Equity interests. (ii) In the event that holders of Class 3 General unsecured Claims are paid in full, each holder of equity Interests shall receive one or more distributions equal to its Pro Rata share of any remaining Liquidation trust Assets after such assets are used to pay in full the claims of Holders of Class 3 General Unsecured claims, and Liquidation Trust expenses, in accordance with the absolute priority rule and the terms of this Combined disclosure statement and plan. Regardless of whether holders of class 4 equity interests receive any recovery from available liquidation trust assets, equity interests shall be terminated, cancelled, released and extinguished as of the effective date. Please consult the company's Joint Plan of Liquidation for further details.¹

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Market Operations- 1-866-776-0800.

¹ See e.g., *In re: Phasebio Pharmaceuticals, Inc. Debtor. Chapter 11 Case No. 22-10995 (LSS) Debtor's First Amended Combined Disclosure Statement And Chapter 11 Plan*